enVVeno Medical Corporation (NASDAQ:NVNO) Sees Significant Increase in Short Interest

enVVeno Medical Corporation (NASDAQ:NVNO) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 532,700 shares, an increase of 24.7% from the February 13th total of 427,100 shares. Approximately 3.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 135,100 shares, the short-interest ratio is presently 3.9 days.

enVVeno Medical Stock Down 3.7 %

Shares of NASDAQ NVNO traded down $0.11 during trading hours on Tuesday, reaching $2.85. 86,844 shares of the stock traded hands, compared to its average volume of 107,560. The company has a market capitalization of $49.98 million, a P/E ratio of -2.21 and a beta of 1.38. enVVeno Medical has a 52-week low of $2.45 and a 52-week high of $6.48. The company’s 50-day simple moving average is $3.24 and its two-hundred day simple moving average is $3.46.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. As a group, sell-side analysts forecast that enVVeno Medical will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On enVVeno Medical

Large investors have recently modified their holdings of the company. Corsair Capital Management L.P. bought a new position in enVVeno Medical during the 3rd quarter worth approximately $390,000. Maven Securities LTD bought a new position in enVVeno Medical during the 3rd quarter worth approximately $295,000. Geode Capital Management LLC grew its position in enVVeno Medical by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after acquiring an additional 10,902 shares during the last quarter. Hohimer Wealth Management LLC bought a new position in enVVeno Medical during the 3rd quarter worth approximately $286,000. Finally, Westside Investment Management Inc. grew its position in enVVeno Medical by 128.0% during the 3rd quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock worth $297,000 after acquiring an additional 49,613 shares during the last quarter. 34.71% of the stock is owned by hedge funds and other institutional investors.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).